Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

NCT05427812 is registered in ClinicalTrials.gov with Ichnos Sciences SA as lead sponsor.

NCT NCT05427812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05427812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Ichnos Sciences SA
Phase
Phase 1/2
Overall status
Terminated
Start date
September 27, 2022
Completion date
November 19, 2024
Enrollment
29 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma